Physician profile
Stephen J Klinger
NPI 1356531677
$11,405.22
in general payments reported to CMS, 2019-2025
32 companies · $3,514 in 2025
The $3,514 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,337 · 2020: $610 · 2021: $1,157 · 2022: $1,589 · 2023: $1,524 · 2024: $1,674 · 2025: $3,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,763 · Consulting Fee: $1,650 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,763.25 |
| Consulting Fee | $1,650.00 |
| Education | $298.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,563.15 | 2019-2025 | Tremfya |
| Abbvie INC. | $2,138.87 | 2019-2025 | |
| Genzyme Corporation | $1,090.78 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $613.24 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $553.88 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $521.68 | 2021-2025 | Dupixent |
| Pfizer INC. | $505.27 | 2019-2025 | |
| Amgen INC. | $482.39 | 2019-2024 | Otezla |
| Ucb, INC. | $354.14 | 2019-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $344.77 | 2019-2024 | Winlevi, Absorica Ld |
| Incyte Corporation | $278.75 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $276.59 | 2019-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $274.06 | 2021-2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $233.93 | 2019-2024 | Arazlo, Jublia, Duobrii |
| Journey Medical Corporation | $214.30 | 2022-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $210.44 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Mayne Pharma Commercial LLC | $153.33 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $122.94 | 2021 | |
| Allergan, INC. | $110.73 | 2019-2022 | |
| Almirall LLC | $65.76 | 2019-2023 | Seysara |
| Mylan Pharmaceuticals INC. | $40.56 | 2019 | |
| Aclaris Therapeutics, INC. | $35.81 | 2019 | |
| Celgene Corporation | $33.52 | 2019 | |
| Merz North America, INC. | $29.72 | 2019 | |
| Organon LLC | $28.36 | 2025 | Vtama |
| Medimetriks Pharmaceuticals, INC. | $21.19 | 2019 | |
| Nabriva Therapeutics, Plc | $20.23 | 2020 | |
| Dermira, INC. | $20.14 | 2019 | |
| Merck Sharp & Dohme LLC | $17.69 | 2019 | |
| Mission Pharmacal Company | $16.48 | 2019 | |
| Cipher Pharmaceuticals US LLC | $16.44 | 2025 | Natroba, Spinosad |
| Arcutis Biotherapeutics, INC. | $16.08 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Klinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.